

73730\_Auto\_Edited - check.docx

**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 73730

**Manuscript Type:** MINIREVIEWS

**Clinical challenge for gastroenterologists–Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review**

Gastrointestinal involvement in systemic mastocytosis

Alessandra Elvevi, Elena Maria Elli, Martina Lucà, Miki Scaravaglio, Fabio Pagni, Stefano Ceola, Laura Ratti, Pietro Invernizzi, Sara Massironi

## **Abstract**

Mastocytosis is a rare and heterogeneous disease characterized by various clinical and biological features that affect different prognosis and treatments. The disease is usually divided into 2 principal categories: cutaneous (CM) and systemic disease (SM). Clinical features can be related to mast cells (MCs) mediators release or pathological MCs infiltration. SM is a disease often hard to identify, and the diagnosis is based on clinical, biological, histological, and molecular criteria with different specialists involved in the patient's clinical work-up. Among all manifestations of the disease, gastrointestinal (GI) symptoms are common, being present in 14-85% of patients, and can significantly impair the quality of life. Here we review the data regarding GI involvement in SM, in terms of clinical presentations, histological and endoscopic features, the pathogenesis of GI symptoms, and their treatment.

**Key Words:** Systemic mastocytosis; gastrointestinal involvement; gastrointestinal symptoms

Elvevi A, Elli EM, Lucà M, Scaravaglio M, Pagni F, Ceola S, Ratti L, Invernizzi P, Massironi S. Clinical challenge for gastroenterologists–Gastrointestinal manifestations of systemic mastocytosis: A comprehensive review. *World J Gastroenterol* 2022; In press

**Core Tip:** Gastrointestinal (GI) involvement is frequent in SM; GI symptoms are frequent (second in frequency only to the itch) and are the main culprits of chronic disorders being a major determinant of quality of life. GI symptoms could be secondary both to MCs mediators release and MCs infiltrations in the GI tract, causing organ dysfunction. Diagnosis of GI involvement in SM is based on clinical and endoscopic suspicion and histologic demonstration of MCs infiltrations in GI mucosa, using immuno-histochemistry (i.e. CD117, tryptase, CD25). Symptomatic treatment is used to control mediators-release symptoms, while cytoreductive therapies necessary to reduce organ dysfunction secondary to MCs infiltration and proliferation.

## INTRODUCTION

Mastocytosis is a rare type of myeloid neoplasm characterized by clonal expansion and accumulation of morphologically and immune-phenotypically abnormal mast cells (MCs) in one or more organ systems<sup>[1]</sup>.

Clinical presentation in mastocytosis patients is heterogeneous<sup>[1,2]</sup>.

Cutaneous mastocytosis (CM) is the skin-limited presentation; it is most common in children, who experience spontaneous regression of skin lesions during the growing.

Systemic mastocytosis (SM) is, on the contrary, a condition of MCs proliferation associated with extra-cutaneous involvement, and it is more frequent in adult patients.

Neoplastic MCs form focal and/or diffuse infiltrates in various internal organs, including the bone marrow (BM), spleen, liver, and gastrointestinal (GI) tract<sup>[2-4]</sup>. Regardless of the type of SM, the BM is involved in virtually all patients.

In 2016, the World Health Organization (WHO) classification of SM identified 5 clinical variants with different prognosis: indolent SM (ISM), smoldering MS (SSM), aggressive SM (ASM), SM with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL)<sup>[5,6]</sup>. Advanced SM (ASM, SM-AHN, and MCL) is generally associated with a poor outcome, whereas ISM patients usually have a comparable life expectancy in comparison with the general population<sup>[1,2]</sup>.

In recent years, knowledge of the pathophysiology of mastocytosis has improved. Particularly, research has found that a recurrent activating D816V KIT mutation, located in the phosphor-transferase domain (PTD) of the receptor, is detectable in more than 80% of adult patients with SM<sup>[7,8]</sup>. Further genetic alterations, usually involved in myeloid malignances pathogenesis, are often found in advanced forms of SM. These mutation are associated with aggressive disease and poor prognosis<sup>[9]</sup>.

For many years, mastocytosis has been considered an orphan disease, and this might be an explanation for difficult prevalence estimation. A reported prevalence of SM of 9.56 per 100,000 persons<sup>[10]</sup> is probably underestimated; in the last few years improvement of knowledge of the disease and availability of diagnostic tests suggested a higher

prevalence, being, according to literature, 21 per 100,000 inhabitants in the adult population<sup>[11]</sup>.

Mastocytosis diagnosis is based on the identification of atypical MCs in the affected tissue, according to the well-established WHO criteria, based on morphological, histological, cytofluorimetric, and molecular features<sup>[5,6]</sup> (Table 1). When the major and at least one minor SM criterion or three minor SM criteria are detected, the diagnosis SM is established. SM patients can be further sub-classified depending on the presence of B (organ involvement without organ failure) or C (organ involvement with organ dysfunction) findings, defining MCs burden or disease aggressiveness, respectively<sup>[1,5,6]</sup> (Table 2).

The severity of the symptoms associated with mastocytosis may vary from mild to life-threatening<sup>[2]</sup>. In general, symptoms occurring in SM are mainly due to the release of chemical mediators from the MCs, such as histamine, heparin, and eosinophil chemotactic factor and thus produce symptoms associated with an allergic reaction, although a true allergic trigger may not be identified. In ASM, where MCs infiltration occurs, a decrease in blood cells (cytopenia), break-down of bones (osteolysis), swelling of the lymph nodes (lymphadenopathy), swelling of the liver (hepatomegaly), impaired liver function, ascites or portal hypertension and malabsorption may occur<sup>[1,12,13]</sup>.

Symptom-directed treatment should be considered in all SM patients<sup>[2]</sup>. Supportive therapies for SM are directed at MCs degranulation symptoms (histamine-receptors 1 (H1) and 2 (H2) antagonists, proton pump inhibitors (PPI), leukotriene antagonist, sodium cromolyn, corticosteroid), symptomatic skin disease (Psolaren plus ultraviolet A (PUVA) photo-chemotherapy, corticosteroids) and/or osteopenia/osteoporosis/pathologic fractures (bisphosphonate, cytokine/immunomodulatory drugs)<sup>[2,14,15]</sup>. Treatment goals for ISM patients are primarily directed towards anaphylaxis prevention and symptom control/osteoporosis treatment. Patients with advanced SM frequently need MCs cytoreductive therapy to ameliorate disease-related organ dysfunction<sup>[2]</sup>. High response rates have been seen with small-molecules inhibitors that target mutant-KIT, including midostaurin (Food and Drug

Administration and European Medicine Agency approved) or avapritinib (Food and Drug Administration approved)<sup>[2,16-19]</sup>.

In this review, we sought to focus on clinical, pathophysiological, histological, and therapeutic aspects of gastrointestinal (GI) tract involvement in SM.

## **2. GI CLINICAL MANIFESTATIONS OF SM**

GI involvement in the clinical presentation of SM has been reported to vary from 15% to 85%. The wide range of variability is probably due to variable definitions of GI symptoms and differences in the attention on GI involvement in the case series available in the literature<sup>[20]</sup>.

However, among all clinical manifestations, GI symptoms appear to be second in frequency only to the itch<sup>[21]</sup> and are the main culprits of chronic disorders being a major determinant of quality of life (QoL)<sup>[20-22]</sup>.

GI symptoms can be varied and may be independent of a clear GI involvement with mastocytes' infiltration<sup>[23]</sup>. In addition, GI manifestations may occur in absence of typical cutaneous manifestations with GI dysfunction being observed in both cutaneous mastocytosis and SM<sup>[24]</sup>. Although the gastro-enteric tract involvement has been described in all SM variants, both the frequency and the type of GI symptoms vary according to the SM subtype.

GI symptoms associated with SM are often non-specific and mimic common conditions such as irritable bowel syndrome, inflammatory bowel disease or celiac disease, with recurrent abdominal pain, nausea, vomiting, gastro-esophageal reflux disease, diarrhea and bloating, until more severe pictures characterized by long-standing, persistent, and intractable diarrhea with malabsorption occurs<sup>[23]</sup>. Also peptic ulcer disease represents a GI manifestation of SM, causing gastro-duodenal ulceration in up to 50% of cases<sup>[25]</sup> with possible severe GI bleeding, sustained by the large amount of histamine released by mast cells (table 3).

## **3. PATHOPHYSIOLOGY OF GASTROINTESTINAL (GI) INVOLVEMENT**

From the pathophysiological point of view, these symptoms are caused by several mechanisms. Activation of MCs causes alteration in epithelial and neuromuscular function. MCs represent 2% of the cells present on the intestinal mucosa of the GI tract<sup>[26]</sup>; they are responsible for a series of regulatory functions, concerning the barrier functions and vascular mucosal permeability, regulate the secretion of GI hormones, modulate peristalsis and the pain perception threshold, regulate the endothelial barrier and chemotaxis of immune cells. They, therefore, intervene in the regulation of the inflammatory response and, as recently described, <sup>24</sup> they drive the immune response by attracting both granulocytes and lymphocytes and innate defense mechanisms such as enhanced epithelial secretion, peristalsis, and alarm programs of the enteric nervous system<sup>[26,27]</sup>.

Activated MCs release various inflammatory mediators, which determine intestinal motility alteration, visceral sensitivity alteration, and mucosal and epithelial gut barrier function alteration. Furthermore MCs inflammatory mediators determine hypersecretion and increased motility, causing diarrhea and abdominal pain. In the more advanced and aggressive stages, there is a direct MCs infiltration of the GI tract and the pathogenic mechanisms change.

The GI tract can be involved in any phase of SM and pathophysiological mechanisms are different. As well as reported for other extra-hematological manifestations of SM, in the initial and indolent forms of SM, the gut is a target of mediators released by MCs and functional disorders are more expressed, with mediators-related functional diarrhea, abdominal pain, motor dyspepsia.

Thereafter, with the massive and persistent mediators' release, organic lesions appear, such as peptic disease. The main mediator released by MCs is histamine which exerts different effects on both the upper and lower gastrointestinal tract. Histamine interacts with H<sub>2</sub> receptors, promoting the secretion of hydrochloric acid, resulting in gastroesophageal reflux disease, gastritis, and peptic ulcer.

The peptic ulcer due to the increase in histamine-related acid secretion is a condition not rarely observed in SM and it is largely underestimated: it is reported in up to 40% of



patients with SM. It does not correlate with circulating markers, in particular with circulating histamine; therefore, it is to be hypothesized with a low threshold of suspicion and to be investigated with gastroscopy. Moreover, peptic ulcer bleeding in MS is also reported in up to 11 % of patients<sup>[25]</sup>.

Histamine also interacts with the H1 receptors, regulating the gut smooth muscle contraction, with impaired peristalsis and motility disorders, clinically resulting in dysmotility-like dyspepsia and functional diarrhea, observed in patients in the early stages of SM.

Besides the GI effects of histamine, other transmitters are released in the course of SM, including prostaglandins and serotonin, which have various effects including effects mainly on the neuromuscular junction of the GI tract, with consequently impaired motility and visceral hypersensitivity. Again, patients present nausea, vomiting, and abdominal pain, worsened by the reduction of the pain threshold.

In the course of mastocytosis, diarrhea is often associated with flushing. Therefore, is important to distinguish “wet flushing”, associated with profuse sweating and “dry flushing”, without sweating (table 3). In SM dry flushing is observed, whereas “wet flushing” is more related to physiological or para-physiological causes.

In the more advanced and aggressive stages of MS, the manifestations are mainly related to the gut MCs infiltration of the GI wall, which impairs both the barrier functions and the absorbing functions, and the pathogenic mechanisms of diarrhea change from a functional to organic diarrhea. As the disease progresses, the clinical picture evolves into malabsorption, progressive caloric-protein malnutrition, vitamin deficiency, deterioration of the patient's condition, worsening of osteoporosis, already present in these patients, and finally anasarca, due to a complete impaired gut absorption and barrier function.

### *3.1. Mast cell mediators-related GI abnormalities*

The release of a great amount of histamine and other peptides contained in MCs granules has been implicated in the pathogenesis of a variety of functional GI manifestations in



SM including diarrhea, bloating, nausea, vomiting, abdominal pain, peptic ulcer disease, and related GI bleeding.

A recent multicenter French study analyzing a cohort of 83 patients affected by SM has demonstrated that GI symptoms are more frequent in SM patients compared to matched healthy subjects. Moreover, SM is correlated with a significantly greater risk of developing peptic ulcer disease especially duodenal ulcers<sup>[28]</sup>.

Diarrhea, bloating and abdominal pain have been reported as the most frequent SM-associated GI disturbances in several studies <sup>[20,22,25,29]</sup>.

Abdominal pain has been described in different case series with a wide range of frequency 12% to 100%. Of note, Cherner and colleagues<sup>[25]</sup> identified two different types of abdominal pain. The majority of SM patients suffered from an abdominal pain of dyspeptic nature, defined as an epigastric pain responsive to antacids and histamine type 2 receptor antagonists and with a high incidence of peptic disease on upper gastrointestinal endoscopic examination. A minority of patients complained of non-dyspeptic pain associated with bloating that did not benefit from histamine 2 receptor antagonists and antacids and was associated with normal endoscopic investigations. While the pathogenesis of the first pain type may be easily correlated to increased acid secretion, the non-dyspeptic pain type is more likely related to intestinal motility disturbances and a lower pain threshold caused not only by an increased release of histamine but also by other mediators such as serotonin, prostaglandins, and neuropeptides.

Functional diarrhea has been reported in several series of SM patients with a range from 14% to 100%. The presence of diarrhea has been described as an episodic increase in bowel movements with subsequent emission of liquid stool that may or may not be associated with a fecal weight > 200 g/d<sup>[20]</sup>. It may be related to increased gastric acid secretion with mechanisms similar to Zollinger Ellison syndrome and/or to increased bowel motility induced by prostaglandin D2 secretion, as there is evidence of cases of diarrhea responsive to aspirin administration<sup>[30]</sup>.

In contrast, the presence of steatorrhea has been correlated with a condition of malabsorption characteristic of advanced mastocytosis with extensive mucosal and submucosal infiltration with MCs.

Nausea and vomiting have been described less frequently and usually as components of syndromic disorders that include also palpitations, flushing, abdominal cramps, and diarrhea generally exacerbated by the ingestion of certain substances, such as alcohol and medications, or contact with inflammatory mediators, which stimulate MCs degranulation.

The absence of specific colonic symptoms does not mean that the colon or rectum are not involved. In particular, rectal manometric studies show a lower distention threshold to induce pain or rectal urgency; patients complain of reduced rectal compliance or overactive rectal contractility.

### 3.2 Peptic ulcer disease

One of the most common mediator-related clinical signs, which over time can generate organic lesions and GI organic damage, is related to gastric acid hypersecretion secondary to hyper-histaminic state, which leads to dyspeptic pain and digestive ulcer disease.

A prospective study shows that peptic ulcer in SM is common, up to 50% of patients<sup>[25]</sup>. It is usually symptomatic and associated with gastric acid hypersecretion and elevated basal acid output (BAO)<sup>[31]</sup>. In some patients, BAO can reach the Zollinger-Ellison range so that may even cause signs and symptoms of the syndrome itself<sup>[20]</sup>. Of interest, a particular form of CM, the so-called *telangiectasia macularis eruptiva perstans* (TMEP) also known as paucicellular mastocytosis has been associated with peptic giant gastroduodenal ulcer<sup>[32]</sup>. Other acid-related complications have been reported such as ulcer perforation, and severe esophagitis. Moreover, up to 11% of SM affected patients will manifest peptic ulcer bleeding during the disease course. However, so far there has been no evidence of a consistent relationship between the level of serum histamine and the presence of ulcer disease or gastric acid output. Despite the increased circulating

histamine level, most patients keep acid secretion within normal levels, in some cases, it has been observed even achlorhydria<sup>[31]</sup>. The variability in the response to circulating histamine may relate to partial inactivity of circulating histamine, differences between circulating histamine and gastric tissue histamine, the intervention of unknown cofactors in the stimulation of oxyntic cells, as well as the theory of possible desensitization of parietal cells that can even justify the rare cases of complete achlorhydria<sup>[20]</sup>.

### 3.3. Mast cell infiltration-related GI abnormalities

In patients with advanced SM, the B and C findings (Table 2) become prevalent to functional GI symptoms. B GI-findings indicate organ involvement without organ dysfunction, while C GI- findings refer to the advanced stage where both organ infiltration and dysfunction coexist and is associated with a poor prognosis<sup>[6]</sup>. They include malabsorption, weight loss, organo-megaly (spleen, liver), until full-blown organ dysfunction that leads to hepatic failure and ascites.

Malabsorption based on quantitative stool fat analysis, D-xylose, and Schilling tests has been found to occur in one-third of SM patients and is usually mild<sup>[32]</sup>.

Thus, it is important to consider mastocytosis in the diagnostic work-up of chronic and intractable diarrhea especially when the endoscopic presentation seems to be suggestive. Both the small and the large intestine can undergo permanent alterations, which contribute to the genesis of diarrhea and malabsorption. Over time, patients could develop real intestinal malabsorption syndrome with vitamin A and D deficiency, overt osteomalacia and osteoporosis, protein-energy malnutrition (PEM), and anasarca.

The whole gastrointestinal tract may be involved in SM with varying degrees.

Liver involvement in SM can range from abnormal liver function test alone up to hepatomegaly due to MCs and eosinophils infiltrates in portal triads. Initial fibrosis can evolve in cirrhosis with worsening portal hypertension sustained by simultaneous splenomegaly with or without hypersplenism and ultimately ascites and upper digestive bleeding from esophageal varices. Of note, mastocytosis is one of the causes of non-cirrhotic portal hypertension<sup>[33]</sup>, sustained by pre-sinusoidal and sinusoidal mechanism

18 through the infiltration of inflammatory mast cells within the portal vein and obstruction of the sinusoids<sup>[34]</sup>. In this setting, we can also observe vascular alteration like portal hypertension, veno-occlusive disease (8%) and Budd-Chiari syndrome.

No studies have identified how many patients with SM develop portal hypertension, but in real medical practice, clinicians have to keep in mind that it can occur without associated advanced liver disease, further increasing the risk of upper GI bleeding.

18 A study of 24 cases of SM involving the GI tract found only 3 patients with liver involvement, but it turns out that liver involvement correlates with more aggressive disease<sup>[23]</sup>. Moreover, as liver failure occurs, it contributes to worsening malnutrition and hypoalbuminemia that are already determined by intestinal insufficiency.

#### **4. ENDOSCOPIC FINDINGS IN SM**

Even though no remarkable endoscopic findings could be found<sup>[4]</sup>, there are several endoscopic pictures described in SM, and endoscopic findings could be secondary both to MCs mediators release and to MCs infiltration in GI wall or liver.

##### *4.1. Upper gastrointestinal endoscopy*

At upper GI endoscopy, peptic disease (esophagitis, esophageal strictures, peptic ulcer) is one of the most frequent findings in patients with SM<sup>[21]</sup>.

According to the literature, upper GI involvement could be found in up to 40% of SM patients undergoing endoscopy<sup>[25]</sup> and may be sustained by chlorhydric acid hypersecretion. However, its pathogenesis is still uncertain: peptic disease is thought to be secondary to gastric acid hypersecretion sustained by elevated histamine plasma levels, but data from literature are controversial: 10 hypersecretion of gastric acid does not seem to be consistently related to the level of serum histamine levels measured. It may however be possible that a relationship between tissue concentration of histamine and GI manifestations can exist<sup>[25]</sup>.

While esophagitis and, when untreated, esophageal strictures are thought to be secondary to mediator release, esophageal varices could be accounted for SM endoscopic findings when liver infiltration is present; this infiltration determines intrahepatic portal hypertension with esophageal and gastric varices development<sup>[33–35]</sup>.

Exploration of stomach and duodenum could show urticaria-like lesions in the antrum of the stomach, diffuse telangiectasia, multiple erosions of gastric and/or duodenal mucosa (Figure 1) and peptic ulcer; these findings are thought to be secondary to MCs mediators' release (i.e. histamine, serotonin, prostaglandins, and neurotensin). When atypical mastocytes infiltration occurs, nodular mucosal lesion of the stomach and/or duodenum can be found<sup>[21,36,37]</sup>.

#### *4.2. Small bowel endoscopy and colonoscopy*

Small bowel, as well as other digestive tracts, could be involved by SM; from the review of literature, most common findings during small bowel exploration are diffuse telangiectasia, thickened jejunal folds, scalloped folds, and diffuse nodularity<sup>[21,36]</sup>. As for the upper GI tract, diffuse telangiectasia and thickened jejunal folds are thought to be secondary to MCs mediators release, while scalloped folds and diffuse nodularity are thought to be secondary to MCs infiltration in the GI wall<sup>[21]</sup>.

Colonoscopy in patients with SM can reveal diffuse telangiectasia and/or urticarial lesion, patchy mucosal erythema, as well as mucosal edema, mucosal friability, loss of vascular patterns, and diffuse nodularity. Moreover, adding indigo carmine dye spraying, could be useful to enhance yellowish-white polypoid lesions and yellowish-white nodular or granular mucosal lesions<sup>[36,38,39]</sup>.

As for the other GI tracts, mucosal erythema and edema, mucosal friability are thought to be secondary to MCs mediators release, while loss of vascular patterns and nodular and /or polypoid lesions are thought to be secondary to MCs infiltration into the bowel wall<sup>[21]</sup>.



Unfortunately, none of these endoscopic signs is specific for GI involvement of SM; hence, biopsy specimens of GI wall should always be performed, in order to have histological diagnostic confirmation of GI involvement.

## **5. HISTOPATHOLOGICAL ASPECT IN SM**

Mast cells (MCs) are unique granulated cells (~20 µm), absent in peripheral blood, they develop in situ from CD34-positive or c-Kit- positive progenitor cells<sup>[40]</sup>. MCs are distributed throughout many tissues including the gastrointestinal mucosa. They enable an immune function in response to a diversity of exogenous substances in the gut lumen<sup>[41]</sup>.

Within the gut, two subpopulations can be distinguished: the mucosal reactive MCs, which may dramatically increase in response to immune stimuli and are dependent on T lymphocytes<sup>[42,43]</sup> and the submucosal MCs that can act in the regulation of intestinal permeability, secretion, peristalsis, nociception, immunity, and angiogenesis<sup>[44]</sup>. The histologic appearances of the GI mucosa in SM patients are incompletely described<sup>[45]</sup>. Results of mucosal mast cell quantitation have similarly been mixed with some studies reporting increased, decreased, and normal numbers of mucosal mast cells in patients with SM compared with controls<sup>[46]</sup>.

The mean normal value of MCs count in normal GI mucosa is yet to be validated in large patient cohorts; most studies consider a cutoff of 20 MCs per high-power field (HPF) within the lamina propria, this value being 2 standard deviations above that found in the general population<sup>[47,48]</sup>.

As MCs infiltrate can be focal and mild, the diagnosis of mastocytosis in GI mucosal biopsies can be challenging; hence multiple biopsies are necessary in order to improve diagnostic yield<sup>[28]</sup>.

In almost all cases of SM involving the GI tract, the number of intramucosal MCs is substantially increased<sup>[23]</sup> and MCs group together, forming pathognomonic compact micronodular or band-like infiltrates. Tiny clusters of cells, with a predominant sub-epithelial distribution, appear in different shapes, varying from rounded cells with a

moderate amount of pale and eosinophilic cytoplasm to ovoid and spindle-shaped cells with scant cytoplasm. Those diagnostic infiltrates may be small but should consist at least of 15 clusterings<sup>[23]</sup>.

Hematoxylin and eosin staining are not a definitive method for MCs detection, hence special staining are required, such as toluidine blue staining and Immuno-Histo-Chemical (IHC) panels using tryptase, CD117 and CD25<sup>[49]</sup>. Comparison between these techniques confirmed stem cell factor receptor kit (c-kit, CD117) being the most accurate technique<sup>[50]</sup>. The CD117 is expressed on all types of MCs independently on the maturation and activation status; in SM, c-Kit is often expressed in MCs in a mutated and constitutively activated form. In these patients, MCs aberrantly displays CD25, a diagnostic marker of neoplastic MCs in all SM variants<sup>[51]</sup>. Therefore, CD117 is sensitive, but not specific for MCs; tryptase is less sensitive, but more specific. Both CD117 and tryptase are not diagnostic of the neoplastic nature, whereas CD25 expression is considered a hallmark of MCs atypia<sup>[4]</sup> (Figure 2).

SM may involve other GI organs like the liver; the main site of liver involvement is the portal tract, where MCs may form groups of dense infiltrates within the fibrotic portal triads; because MCs are normally absent in the sinusoid, the presence of scattered MCs in liver sinusoids is also consistent with SM (Figure 3).

## **6. TREATMENT OF GI SYMPTOMS**

Symptom-directed treatments should be considered in all SM patients and are directed at mast cells degranulation symptoms (i.e., nausea, vomiting, abdominal pain, peptic disease, diarrhea)<sup>[2]</sup>.

As first step, patients must recognize and avoid general and specific individual factors that trigger symptoms. These can commonly include physical factors such as heat, temperature changes, some forms of exercise, emotions, stress, sleep deprivation; diagnostic and therapeutic agents such as opiates, NSAIDs, succinylcholine, and agents with tetrahydroisoquinoline, atracurionium, rocuronium, quinolones, foods including those containing or releasing histamine, alcohol; Hymenoptera venoms<sup>[52]</sup>.



Different symptomatic drugs have been proposed for control of GI symptoms: H<sub>2</sub>-antagonists (i.e., Famotidine 10 mg BID, Cimetidine 400 mg BID) are the first-line therapy<sup>[2]</sup>. They act as inverse agonists that combine with and stabilize the inactive conformation of the histamine-receptor, shifting the equilibrium toward the inactive state; in a concentration-dependent manner they inhibit MCs activation and histamine release; although the mechanisms involved have not yet been delineated fully, downregulation of intracellular calcium ion accumulation seems to play a role<sup>[53]</sup>.

Inactivation of histamine receptors reduces histamine effect along GI tract, hence reducing histamine-related symptoms (i.e., diarrhea, abdominal pain, peptic disease).

When histamine-receptor blockers are poorly effective or ineffective, proton pump inhibitors (PPIs, i.e., Omeprazole 20 mg/d, Rabeprazole 20 mg/d, Pantoprazole 40 mg/d) represent second-line therapy<sup>[2]</sup>. Hydrochloric acid is secreted by parietal cells in the oxyntic mucosa that lines the body and fundus of the stomach, as a response to different mediators (i.e. histamine, gastrin, acetylcholine), that activate H<sup>+</sup>/K<sup>+</sup> ATP-ase (i.e. the proton pump) that pumps hydrogen ions (protons) into the lumen in exchange for potassium ions. PPIs block this final step in gastric acid secretion, by blocking H<sup>+</sup>/K<sup>+</sup> ATP-ase irreversibly. They are remarkably effective in the inhibition of gastric acid secretion<sup>[54]</sup>. Considering SM as a hypersecretory condition, it is clear that reducing chloride acid secretion is beneficial in SM patients, because it reduces peptic symptoms, peptic disease and/or diarrhea.

Sodium cromolyn (100-200 mg QID 30 minutes before meals and bedtime) represents the third-line therapy, when H<sub>2</sub> antagonists and PPIs are ineffective<sup>[2]</sup>. It works as an inhibitor of histamine release and cell membranes stabilizer: cromolyn sodium caused weak inhibition of histamine release, but, different studies showed its action on other mediators, involved in mast cells degranulation: it inhibits prostaglandin D<sub>2</sub> release and TNF $\alpha$  release from mast cells, hence reducing MCs degranulation and mediators-release<sup>[55]</sup>. Reducing mediators-release should help reducing GI symptoms.

Pardanani<sup>[2]</sup> has proposed systemic corticosteroid (i.e. Prednisone 0.5-1 mg/kg/d starting dose; taper as feasible based on response/tolerance), as the fourth line of therapy for GI

symptoms, resistant to previous symptomatic therapies.<sup>6</sup> Corticosteroids are potent anti-inflammatory drugs widely used in the treatment of allergic and inflammatory diseases.<sup>6</sup> They also showed an in-vitro inhibition of MCs mediators' release.<sup>6</sup> Systemic administration of corticosteroids has been used in patients with mastocytosis. While this treatment appears to improve control of some mediators-release symptoms, it has not been proved to reduce MCs numbers significantly in patients with mastocytosis<sup>[56]</sup>. Of note,<sup>6</sup> systemic corticosteroids have been useful in decreasing the malabsorption and ascites in some of these patients<sup>[57]</sup>. It has also been suggested the use of oral budesonide, but further studies are needed to determine its efficacy.

In advanced SM, treatments interfering with MCs proliferation and survival are used<sup>[2]</sup>. GI symptoms secondary to organ infiltration could also benefit from cytoreductive therapies, as 2-Chlorodeoxyadenosine (cladribine or 2-CdA) or Interferon-alfa<sup>[58]</sup>. Young and otherwise healthy ASM patients, allo-SCT is the only option for a sustained response<sup>[59]</sup>. Promising effects have been seen with the use of targeted therapy on mutated-KIT,<sup>2</sup> which occurs in most SM patients<sup>[2]</sup>. Midostaurin (PKC412) is the first kit-inhibitor recent<sup>2</sup> approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of Advanced SM<sup>[16,17]</sup>. It has<sup>8</sup> *in vitro* activity against kinase domain KIT mutants (D816Y and D816V). In the global Phase 2 CPKC412D2201 trial<sup>[18]</sup>, 116 patients with advanced SM were enrolled; patients were<sup>19</sup> treated with PKC412 at 100 mg BID. The overall response rate (ORR) per conventional criteria was 60% with 45% having a major response and 15% having a partial response, but often not sustained. In particular, concerning GI involvement, reversal of organ damage was reflected by normalization of hypoalbuminemia (58%),<sup>7</sup> improvement in liver function test abnormalities (44%- 58%), and/or reversion of weight loss (25%). Patients reported improvement of disease-related symptoms with treatment. Therefore,<sup>5</sup> the most common drug side effects (all grades/grades 3-4) were nausea (79%/6%), vomiting (66%/6%), diarrhea (54%/3%), and fatigue (28%/9%), in addition to hematological toxicity, in term of grade 3-4 of<sup>26</sup> neutropenia, anemia, and thrombocytopenia, occurring in 24%, 41%, and 29% of patients, respectively.

Avapritinib<sup>[19]</sup>, a KIT and PDGFRA inhibitor, showed promising results; other medications potentially effective for SM patients are under investigation<sup>[2]</sup>. Further optimization of treatment with tyrosine-kinase inhibitors in order to improve patients' quality of life is still needed.

## **CONCLUSION**

<sup>1</sup> Mastocytosis is a rare and heterogeneous disease characterized by various biological and clinical features with different prognosis and treatments. The disease is usually divided into 2 principal categories: CM and SM. Clinical features can be related to MCs mediators release or pathological MCs infiltration. The diagnosis of SM is based on clinical, biological, histological, and molecular criteria, according to WHO 2016 classification. <sup>25</sup> A proper patient's workup requires a multidisciplinary approach including gastroenterologists, endoscopists, hematologists, and pathologists. Among all manifestations of the disease, GI symptoms are common, being present in 15-85% of the patients and can significantly impair the quality of life. Here we review the data regarding GI involvement in SM, in terms of clinical presentations, histological features, <sup>1</sup> the pathogenesis of GI symptoms and their treatment. The most frequent GI symptoms are abdominal pain, diarrhea, nausea, and vomiting. GI lesions may involve all the digestive tract, from the esophagus to the rectum. The histological diagnosis of GI involvement is difficult. The treatment of GI symptoms aims to prevent and limit MCs degranulation and/or its consequences and more rarely to control tumoral mast cells infiltration. The diagnosis of mastocytosis should be considered in the case of unexplained severe GI disorders.

# 24%

SIMILARITY INDEX

### PRIMARY SOURCES

- |          |  |                |
|----------|--|----------------|
| <b>1</b> | <a href="https://tmsforacure.org">tmsforacure.org</a><br><small>Internet</small>   | 119 words — 2% |
| <hr/>    |  |                |
| <b>2</b> | <a href="https://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a><br><small>Internet</small>   | 103 words — 2% |
| <hr/>    |  |                |
| <b>3</b> | Annalisa Capannolo, Fabiana Ciccone, Giovanni Latella. "Mastocytic Enterocolitis and the Role of Mast Cells in Functional and Inflammatory Intestinal Disorders: A Systematic Review", Digestive Diseases, 2018<br><small>Crossref</small> | 91 words — 2%  |
| <hr/>    |  |                |
| <b>4</b> | <a href="https://rarediseases.org">rarediseases.org</a><br><small>Internet</small>   | 80 words — 2%  |
| <hr/>    |  |                |
| <b>5</b> | Animesh Pardanani. "Systemic mastocytosis in adults: 2021 update on diagnosis, risk stratification and management", American Journal of Hematology, 2021<br><small>Crossref</small>  | 72 words — 1%  |
| <hr/>    |  |                |
| <b>6</b> | Gianni Marone, Giuseppe Spadaro, Francescopaolo Granata, Massimo Triggiani. "Treatment of mastocytosis: pharmacologic basis and current concepts", Leukemia Research, 2001<br><small>Crossref</small>                                      | 66 words — 1%  |
| <hr/>    |  |                |
| <b>7</b> | Animesh Pardanani. "Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification   | 56 words — 1%  |

- 
- 8 Federica Irene Grifoni, Mariarita Sciumè, Valerio Pravettoni, Fabio Massimo Ulivieri et al. "A case report of systemic mastocytosis associated with multiple hematologic non-mast cell lineage diseases", Hematological Oncology, 2019  
47 words — 1%  
Crossref
- 
- 9 mafiadoc.com  
Internet  
47 words — 1%
- 
- 10 www.wjgnet.com  
Internet  
46 words — 1%
- 
- 11 Arguedas, M.R.. "Systemic mastocytosis and giant gastroduodenal ulcer", Gastrointestinal Endoscopy, 200110  
45 words — 1%  
Crossref
- 
- 12 Mariana Castells, Joseph Butterfield. "Mast Cell Activation Syndrome and Mastocytosis: Initial Treatment Options and Long-Term Management", The Journal of Allergy and Clinical Immunology: In Practice, 2019  
44 words — 1%  
Crossref
- 
- 13 Roberta Zanotti, Ilaria Tanasi, Andrea Bernardelli, Giovanni Orsolini, Patrizia Bonadonna. "Bone Marrow Mastocytosis: A Diagnostic Challenge", Journal of Clinical Medicine, 2021  
42 words — 1%  
Crossref
- 
- 14 Stuart Jon Spechler. "Proton Pump Inhibitors", Medical Clinics of North America, 2018  
42 words — 1%  
Crossref
- 
- 15 www.bloodjournal.org

---

16 Magda Zanelli, Marco Pizzi, Francesca Sanguedolce, Maurizio Zizzo et al. "Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach", *Cancers*, 2021 33 words — 1%  
Crossref

---

17 [www.uni-ulm.de](http://www.uni-ulm.de) 32 words — 1%  
Internet

---

18 Thomas R. McCarty, Adelina Hung, Arpan Mohanty, John I. Allen. "Systemic Mastocytosis Complicated by Non-Cirrhotic Portal Hypertension and Variceal Bleeding", *ACG Case Reports Journal*, 2017 31 words — 1%  
Crossref

---

19 Animesh Pardanani. "Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management", *American Journal of Hematology*, 2016 30 words — 1%  
Crossref

---

20 Hejin P. Hahn, Jason L. Hornick. "Immunoreactivity for CD25 in Gastrointestinal Mucosal Mast Cells is Specific for Systemic Mastocytosis", *American Journal of Surgical Pathology*, 2007 28 words — 1%  
Crossref

---

21 [www.mdpi.com](http://www.mdpi.com) 26 words — 1%  
Internet

---

22 Claus Bachert, Olga Krysko, Philippe Gevaert, Margot Berings, Claudina Perez-Novoa, Koen van Crombruggen. "Nasal Immunity, Rhinitis, and Rhinosinusitis", Elsevier BV, 2015 23 words — < 1%  
Crossref

---

23 Animesh Pardanani. "Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management", American Journal of Hematology, 2018 17 words — < 1%  
Crossref

---

24 [link.springer.com](https://link.springer.com) 16 words — < 1%  
Internet

---

25 [www.researchgate.net](https://www.researchgate.net) 16 words — < 1%  
Internet

---

26 Marie-Olivia Chandesris, Gandhi Damaj, Olivier Lortholary, Olivier Hermine. "Clinical potential of midostaurin in advanced systemic mastocytosis", Blood and Lymphatic Cancer: Targets and Therapy, 2017 13 words — < 1%  
Crossref

---

27 Alexander Coltoff, John Mascarenhas. "Relevant updates in systemic mastocytosis", Leukemia Research, 2019 12 words — < 1%  
Crossref

---

28 [docslide.us](https://docslide.us) 12 words — < 1%  
Internet

---

EXCLUDE QUOTES ON  
EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES < 12 WORDS  
EXCLUDE MATCHES < 12 WORDS